Tags

Type your tag names separated by a space and hit enter

A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.
Biol Blood Marrow Transplant. 2003 Dec; 9(12):766-71.BB

Abstract

The prognosis of patients with primary refractory acute myelogenous leukemia (AML) is poor. Our initial report suggested that some patients could achieve durable remission after allogeneic stem cell transplantation (SCT). Herein, we update our initial experience and report further analysis of this group of patients to determine whether there are pre-SCT prognostic factors predictive of posttransplantation relapse and survival. We reviewed the records of 68 patients who consecutively underwent transplantation at the City of Hope Cancer Center with allogeneic SCT for primary refractory AML between July 1978 and August 2000. Potential factors associated with overall survival and disease-free survival were examined. With a median follow-up of 3 years, the 3-year cumulative probabilities of disease-free survival (DFS), overall survival (OS), and relapse rate for all 68 patients were 31% (95% confidence interval [CI], 20%-42%), 30% (95% CI, 18%-41%), and 51% (95% CI, 38%-65%), respectively. In multivariate analysis, the only variables associated with shortened OS and DFS included the use of an unrelated donor as the stem cell source (relative risk, 2.23 [OS] and 2.05 [DFS]; P =.0005 and.0014, respectively) and unfavorable cytogenetics before SCT (relative risk: 1.68 [OS] and 1.58 [DFS]; P =.0107 and.0038, respectively). Allogeneic SCT can cure approximately one third of patients with primary refractory AML. Cytogenetic characteristics before SCT correlate with transplantation outcome and posttransplantation relapse.

Authors+Show Affiliations

Division of Hematology and Bone Marrow Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA. hfung@coh.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

14677116

Citation

Fung, H C., et al. "A Long-term Follow-up Report On Allogeneic Stem Cell Transplantation for Patients With Primary Refractory Acute Myelogenous Leukemia: Impact of Cytogenetic Characteristics On Transplantation Outcome." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, vol. 9, no. 12, 2003, pp. 766-71.
Fung HC, Stein A, Slovak Ml, et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant. 2003;9(12):766-71.
Fung, H. C., Stein, A., Slovak, M. l., O'donnell, M. R., Snyder, D. S., Cohen, S., Smith, D., Krishnan, A., Spielberger, R., Bhatia, R., Bhatia, S., Falk, P., Molina, A., Nademanee, A., Parker, P., Rodriguez, R., Rosenthal, J., Sweetman, R., Kogut, N., ... Forman, S. J. (2003). A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 9(12), 766-71.
Fung HC, et al. A Long-term Follow-up Report On Allogeneic Stem Cell Transplantation for Patients With Primary Refractory Acute Myelogenous Leukemia: Impact of Cytogenetic Characteristics On Transplantation Outcome. Biol Blood Marrow Transplant. 2003;9(12):766-71. PubMed PMID: 14677116.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. AU - Fung,H C, AU - Stein,A, AU - Slovak,M l, AU - O'donnell,M R, AU - Snyder,D S, AU - Cohen,S, AU - Smith,D, AU - Krishnan,A, AU - Spielberger,R, AU - Bhatia,R, AU - Bhatia,S, AU - Falk,P, AU - Molina,A, AU - Nademanee,A, AU - Parker,P, AU - Rodriguez,R, AU - Rosenthal,J, AU - Sweetman,R, AU - Kogut,N, AU - Sahebi,F, AU - Popplewell,L, AU - Vora,N, AU - Somlo,G, AU - Margolin,K, AU - Chow,W, AU - Smith,E, AU - Forman,S J, PY - 2003/12/17/pubmed PY - 2004/9/10/medline PY - 2003/12/17/entrez SP - 766 EP - 71 JF - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation JO - Biol Blood Marrow Transplant VL - 9 IS - 12 N2 - The prognosis of patients with primary refractory acute myelogenous leukemia (AML) is poor. Our initial report suggested that some patients could achieve durable remission after allogeneic stem cell transplantation (SCT). Herein, we update our initial experience and report further analysis of this group of patients to determine whether there are pre-SCT prognostic factors predictive of posttransplantation relapse and survival. We reviewed the records of 68 patients who consecutively underwent transplantation at the City of Hope Cancer Center with allogeneic SCT for primary refractory AML between July 1978 and August 2000. Potential factors associated with overall survival and disease-free survival were examined. With a median follow-up of 3 years, the 3-year cumulative probabilities of disease-free survival (DFS), overall survival (OS), and relapse rate for all 68 patients were 31% (95% confidence interval [CI], 20%-42%), 30% (95% CI, 18%-41%), and 51% (95% CI, 38%-65%), respectively. In multivariate analysis, the only variables associated with shortened OS and DFS included the use of an unrelated donor as the stem cell source (relative risk, 2.23 [OS] and 2.05 [DFS]; P =.0005 and.0014, respectively) and unfavorable cytogenetics before SCT (relative risk: 1.68 [OS] and 1.58 [DFS]; P =.0107 and.0038, respectively). Allogeneic SCT can cure approximately one third of patients with primary refractory AML. Cytogenetic characteristics before SCT correlate with transplantation outcome and posttransplantation relapse. SN - 1083-8791 UR - https://www.unboundmedicine.com/medline/citation/14677116/A_long_term_follow_up_report_on_allogeneic_stem_cell_transplantation_for_patients_with_primary_refractory_acute_myelogenous_leukemia:_impact_of_cytogenetic_characteristics_on_transplantation_outcome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1083879103002921 DB - PRIME DP - Unbound Medicine ER -